Ambros Therapeutics is moving its pain drug into later-stage development via a reverse merger with Werewolf Therapeutics. Alongside the all-stock transaction, the combined company will raise $150 million in a private placement, positioning it to progress a Phase 3 asset for a pain type that does not respond to currently available medicines, including opioids. The deal underscores how smaller-stage biotechs are using reverse mergers to lock in funding and valuation ahead of pivotal clinical readouts. For Ambros, the path combines capital infusion with an accelerated corporate runway intended to support regulatory filing preparation. As the market continues to scrutinize near-term catalysts, the merger also highlights the importance of late-stage execution for pain franchises, where differentiation and endpoint clarity tend to determine investor confidence.